Maze Therapeutics, Inc.
NASDAQ: MAZE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Coloma
- Employees
- 141
- Headquarters
- South San Francisco, United States
- IPO year
- 2025
- Market cap
- $1.5B
- Website
- https://www.mazetx.com
Loading MAZE…
Loading profile data…Frequently asked questions about MAZE
What does Maze Therapeutics, Inc. (MAZE) do?
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patie...
Where does MAZE trade?
Maze Therapeutics, Inc. (MAZE) trades on the NASDAQ.
What sector is MAZE in?
Maze Therapeutics, Inc. (MAZE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Maze Therapeutics, Inc.?
Jason Coloma is the chief executive officer of Maze Therapeutics, Inc. (MAZE).
Where is Maze Therapeutics, Inc. headquartered?
Maze Therapeutics, Inc. is headquartered in United States.
Does MAZE pay a dividend?
Maze Therapeutics, Inc. (MAZE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MAZE go public?
Maze Therapeutics, Inc. (MAZE) completed its initial public offering in 2025.